Albumin levels predict mortality in sepsis patients with acute kidney injury undergoing continuous renal replacement therapy: A secondary analysis based on a retrospective cohort study
BMC Nephrology — Sheng S, Zhang YH, Ma HK, et al. | February 04, 2022
Researchers herein tested the hypothesis that albumin (ALB) levels are negatively linked with mortality among sepsis patients with acute kidney injury (AKI) undergoing continuous renal replacement therapy (CRRT).
A total of 794 septic patients who were diagnosed with AKI and underwent CRRT were assessed in this secondary analysis.
Findings suggest an independent correlation of the ALB level with prognosis for death at 28 and 90 days after CRRT initiation; a 1 g/dL rise in ALB levels was noted to be independently linked with a 25% and 27% reduction in the risk of death at 28 and 90 days, respectively.
In subgroup analyses and tests for interactions, HCO3 and CRP were identified playing an interactive role in the association.
ROC analysis indicated inadequacy of ALB, SOFA and APACHE-II for clinical applications when used separately.
Researchers recommend practicing caution in considering the conclusion given the various limitations of this study.
Read the full article on BMC Nephrology